Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4⁺ T cell interleukin-2 secretion.

ABSTRACT: Therapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to predict. Therefore, it is important to efficiently assess immunogenicity during the development of complex antibody-based formats. Here, we present an in vitro peripheral blood mononuclear cell-based assay that can be used to assess immunogenicity potential within 3 days. This method involves examining the frequency and function of interleukin (IL)-2-secreting CD4⁺ T cells induced by therapeutic antibodies. IL-2-secreting CD4⁺ T cells seem to be functionally relevant to the immunogenic potential due to their proliferative activit

SUBMITTER: Arata Y 

PROVIDER: S-EPMC10494738 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature